^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYD88 mutation

    i
    Other names: MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D
    Entrez ID:
    4615
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia (NCT05640102)
    Phase N/A
    BeiGene
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    03/03/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    MYD88
    |
    MYD88 mutation • MYD88 L265P • MYD88 wild-type
    |
    Brukinsa (zanubrutinib)
    Ibrutinib + Venetoclax in Untreated WM (NCT04273139)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/09/2020
    Primary completion :
    06/06/2022
    Completion :
    02/01/2028
    BCL2 • MYD88
    |
    MYD88 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    ZR-CHOP in DLBCL With Specific Gene Abnormality (NCT05290337)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    03/22/2022
    Initiation :
    01/04/2022
    Primary completion :
    01/04/2024
    Completion :
    01/04/2026
    TP53 • MYC • MYD88 • CD79B
    |
    TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia (WAL-KU) (NCT02640287)
    Phase N/A
    Central Hospital, Nancy, France
    Completed
    Last update posted :
    08/06/2021
    Initiation :
    02/01/2016
    Primary completion :
    06/01/2020
    Completion :
    07/01/2020
    MYD88
    |
    MYD88 mutation • MYD88 L265P
    Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM) (NCT04183569)
    Phase N/A
    University Hospital, Bordeaux
    Unknown status
    Last update posted :
    04/29/2020
    Initiation :
    02/19/2019
    Primary completion :
    05/01/2020
    Completion :
    05/01/2020
    BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
    |
    CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation